JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT), noting the company’s initial focus on infectious ...

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates ...

J&J has already benefitted from Halozyme’s ENHANZE tech with DARZALEX, and it looks as if OPDIVO might be another blockbuster drug that could benefit from ENHANZE tech. Essentially, Halozyme offers ...

Dr Meredith Edwards, Country Medical Director, Bristol Myers Squibb New Zealand, said, “The funding of OPDIVO as a treatment option for previously treated advanced clear cell renal cell carcinoma ...

Opdivo® (nivolumab) is now funded in New Zealand for eligible patients with metastatic clear cell renal cell carcinoma (RCC) (advanced kidney cancer) after prior anti-angiogenic therapy.

Opdivo gained rapid approval in the US after having gained 'Breakthrough Therapy Designation', and was also identified as a promising innovative medicine (PIM) for lung cancer by the UK's drug ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors’ attention was on technology ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...